Diabetes and cardiovascular disease among older adults: An update on the evidence

Geriatrics and Aging

Volumn 11, Issue 9, 2008, Pages 509-514

  Katz, Pamela ^a   Gilbert, Jeremy ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cardiovascular disease; Diabetes; Metabolic syndrome; Older adults

Indexed keywords

EID: 55849131092     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007;369:750-6.
2. Hornick T, Aron DC. Managing diabetes in the elderly: Go easy, individualize. Clev Clin J Med 2008;75:70-8.
3. Statistics Canada. Portrait of the Canadian population in 2006, by age and sex. July 17, 2007. www12.statcan.ca/english/census06/release/ release_agesex.cfm Accessed September 12, 2008.
4. Hornick T, Aron D. Preventing and managing diabetic complications in elderly patients. Cleve Clin J Med 2008;75:153-8.
5. Kronmal RA, Barzilay JI, Smith NL, et al. Mortality in pharmacologically treated older adults with diabetes: The Cardiovascular Health Study, 1989-2001. PLoS Medicine 2006;3:1883-91.
6. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999;353:617-22.
7. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
8. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.
9. Shepard J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.
10. Canadian Diabetes Association 2008 Clinical Practice Guidelines. Canadian Journal of Diabetes. September 2008;32(Suppl 1): S29, S37, S107, S115, S181.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
12. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III) JAMA 2000;285:2486.
13. Genuth, S, Alberti, KG, Bennett, P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160.
14. Alberti KG et al. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735.
16. Mozaffarian D, Kamineni A, Prineas RJ, et al. Metabolic syndrome and mortality in older adults: The Cardiovascular Health Study. Arch Intern Med 2008;168:969-78.
17. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997;20:135.
18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med 2007;356:2457-71.
19. Gilbert J. Pharmacological treatments for diabetes among older adults: an update. Geriatrics & Aging 2007;10:551-60.
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
21. Holman RR, Paul SK, Bethel A, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359. Epub ahead of print Sept 10.
22. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
23. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
24. Aronow WS. Hypertension and the older diabetic. Clin Geriatr Med 2008;24:489-501.
25. Hypertension in Diabetes Study (HDS) I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-17.
26. Hypertension in Diabetes Study (HDS) LT. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993;11:319-25.
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
28. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.
29. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
30. Whelton PK, Barzilay J, Cushman WC, et al; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). Arch Intern Med 2005;165:1401-9.
31. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-64.
32. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72.
33. Curb JD, Pressel SL, Cutler JA, et al. Effects of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group JAMA 1996;276:1886-92.
34. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340:677-84.
35. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of anti-hypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18:1671-5.
36. Kronenberg HM, Melmed S, Polonsky KS, et al. Williams Textbook of Endocrinology, 11th edition. Saunders Elsevier 2008. Chapter 32, p1475.
37. Collins R, Armitage J, Parish S, et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16.
38. Keech A, Colquhoun D, Best J, et al; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713-21.
39. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
40. Sever PS, Poulter NR, Dalhof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid lowering arm (ASCOTTLLA). Diabetes Care 2005;28:1151-7.
41. Shepherd J, Barter P, Carmena R, et al. Effects of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6.
42. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID Trial. Ann Intern Med 2001;134:931-40.
43. Lewis SJ, Moye LA, Sacks FM, et al. Effects of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
44. Bang LM, Goa KL. Pravastatin: a review of its use in elderly patients. Drugs Aging 2003;20:1061-82.
45. Neil HA, DeMicco DA, Luo D, et al: CARDS Study Investigators. Analysis of efficacy and safety in patients 65-75 years at randomizations: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006;29:2378-84.
46. Walker DB, Jacobson TA. Initiating statins in the elderly: the evolving challenge. Curr Opin Endocrinol Diabetes Obes 2008;15:182-7.
47. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
48. Olsson AG, Schwartz GG, Szarek M, et al. Effects of high-dose atorvastatin in patients > or = 65 years of age with acute coronary syndrome (from the myocardial ischaemia reduction with aggressive cholesterol lowering (MIRACL) study). Am J Cardiol 2007;99:632-5.
49. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
50. Sigal RJ, Kenny GP, Wasserman DH, et al. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006;29:1433-8.
51. Villareal DT, Banks MR, Patterson BW, et al. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity 2008;16:1349-54.
52. Heath JM, Stuart MR. Prescribing exercise for frail elders. J Am Board Fam Pract 2002;15:218-28.
53. Dunstan DW, Daly RM, Owen N, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 2002;25:1729-36.
54. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
55. Abbate S. Expanded ABCs of Diabetes. Diabetes Care 2003;21:128-33.